Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-03 · accession 0001883850-24-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-03 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $399.66 | +34.0K | 64.0K | +113% | +$13.59M |
| D | 2024-01-04 | 2024-01-03 | REGN | LAROSA JOSEPH J | EVP GC, Secret | F - Tax | $912.30 | -24.5K | 39.5K | -38% | -$22.34M |
| D | 2024-01-04 | 2024-01-03 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $0.00 | -34.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-03 | M | A | 34,000 | $399.66 | 64,036 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-03 | F | D | 24,493 | $912.30 | 39,543 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-03 | M | D | 34,000 | $0.00 | 0 | D | $399.66 · — to 2024-12-16 | 34,000 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |